Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Adverum Biotechnologies, Inc.
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.
IPO Date: May 12, 2016
Sector: Healthcare
Industry: Biotech
Market Cap: $69.57M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.21 | 3.60%
Avg Daily Range (30 D): $0.17 | 4.73%
Avg Daily Range (90 D): $0.18 | 4.36%
Institutional Daily Volume
Avg Daily Volume: .74M
Avg Daily Volume (30 D): .34M
Avg Daily Volume (90 D): .22M
Trade Size
Avg Trade Size (Sh.): 177
Avg Trade Size (Sh.) (30 D): 143
Avg Trade Size (Sh.) (90 D): 109
Institutional Trades
Total Inst.Trades: 1,058
Avg Inst. Trade: $1.82M
Avg Inst. Trade (30 D): $1.48M
Avg Inst. Trade (90 D): $1.48M
Avg Inst. Trade Volume: .03M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.18M
Avg Closing Trade (30 D): $.65M
Avg Closing Trade (90 D): $.65M
Avg Closing Volume: 29.67K
       
News
Apr 17, 2025 @ 4:58 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
Mar 4, 2025 @ 3:55 PM
2025 Market Prospects of Adeno-Associated Virus Ve...
Source: Researchandmarkets.Com
Mar 3, 2025 @ 9:01 PM
Adverum Biotechnologies Initiates ARTEMIS Phase 3 ...
Source: N/A
Feb 25, 2025 @ 12:00 PM
Adverum Biotechnologies to Participate in the Cowe...
Source: N/A
Oct 22, 2024 @ 5:00 PM
Gene Therapy Clinical Trial Pipeline Gains Momentu...
Source: Delveinsight
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-6.62 $-1.98 $-6.62
Diluted EPS $-6.62 $-1.98 $-6.62
Revenue $ 1M $ M $ 1M
Gross Profit $ $ $
Net Income / Loss $ -130.93M $ -40.93M $ -130.93M
Operating Income / Loss $ -139.16M $ -42.62M $ -139.16M
Cost of Revenue $ $ $
Net Cash Flow $ -14.35M $ -32.2M $ -14.35M
PE Ratio    
Splits
Mar 21, 2024:   10:1